Background and Objectives In Caucasians, fetal/neonatal alloimmune thrombocytopenia (FNAIT) is most commonly due to maternal HPA-1a antibodies. HPA-1a typing followed by screening for anti-HPA-1a antibodies in HPA-1bb women may identify first pregnancies at risk. Our goal was to review results from previous published studies to examine whether the maternal antibody level to HPA-1a could be used to identify high-risk pregnancies.
Introduction
The frequency of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT) (<50 9 10 9 /l) secondary to HPA-1a antibodies has been reported to be approximately 1/2500 pregnancies [1] . Clinically, a fetus or neonate with severe FNAIT often displays unexpected bleeding during pregnancy or within a few hours of delivery. Without screening of all pregnancies, there is currently no way to predict the occurrence of FNAIT other than identification of a sibling with FNAIT. Using the obstetric history as a predictor, with a diagnostic sensitivity of only 13%, the majority of severe FNAIT cases are not detected until after delivery [2] . Thus in a nonscreening situation, Tiller et al. reported that only seven to eight cases of FNAIT were detected per year compared with 53 cases when screening was applied [3] .
Development of non-invasive diagnostic tools that can be used to discriminate between pregnancies in need of antenatal treatment is crucial. The current approach by identifying neonates with FNAIT postnatally precludes antenatal treatment and/or precautions during delivery, whereas an antenatal screening programme would ideally allow both antenatal intervention and immediate treatment of severe FNAIT at birth of an affected neonate.
The challenge of an antenatal screening programme is, however, to identify women in whom the risk of severe FNAIT is sufficiently high to justify active treatment during pregnancy to minimize the risk of bleeding complications secondary to FNAIT, whilst not exposing women with milder cases to unnecessary interventions.
The aim of this systematic review was to examine if a relationship can be identified between maternal anti-HPA-1a alloantibody concentration and fetal/neonatal platelet count, which could potentially serve as a noninvasive strategy to identify high-risk pregnancies.
Methods

Study selection and data extraction
The search was applied to the electronic databases MED-LINE, EMBASE and the Cochrane Library from 1946 to 12 January 2016 (Appendix A). Data were independently extracted by two authors (NS, ST).
The included studies met the following criteria: (1) an original study, (2) five or more pregnant women, (3) platelet count and HPA-1a antibody determination and (4) published in English. Details from each included study are summarized in Appendix B. The included studies were divided into two categories: (1) 'Prospective studies' of 'unselected women' identified by an FNAIT screening programme (HPA-1a typing followed by anti-HPA-1a antibody screening) and (2) 'Retrospective studies' of 'selected women' due to an FNAIT child.
All thrombocytopenic neonates (<150 9 10 9 /l) from these studies were included in this review, even those without clinical signs of bleeding.
Assessment of quality
The assessment of the quality of individual primary studies was based on the checklist developed by Fowkes and Fulton and considered the following; whether (1) there was an adequate description of the study population, (2) all eligible patients were screened, (3) a normal sample was included, (4) there were clear definitions of associations, (5) reproducibility of testing was assessed and (6) missing data were reported [4] . The considerable heterogeneity in the measurement of study outcomes did not permit conduction of a meta-analysis; therefore, we performed a descriptive review of included studies. Strategies for inclusion of study subjects, the type of laboratory assay used and the time-point of both maternal and fetal sampling were specially taken into consideration when analyzing the data.
Results
Study selection and characteristics
A total of 5940 publications were identified (Fig. 1 ). Of these, 4692 were screened after duplicates were removed and 93 full-text articles were assessed for eligibility. Sixty-six of the 93 did not report the population or outcome of interest and three were not published in English.
Finally, thirteen of the 27 studies had complete data [2, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , the remainder were duplicates [17] [18] [19] [20] [21] , did not address HPA-1a antibodies [22] [23] [24] [25] , screened all neonates [26] or did not have a sufficient sample size [27] [28] [29] [30] . Three studies were prospective [2, 5, 7] and ten studies were retrospective [6, [8] [9] [10] [11] [12] [13] [14] [15] [16] . Appendix B describes the 13 studies that were included in this review. Appendix C details the 14 studies that were not included.
The assessment of the quality of studies is shown in Fig. 2 . Nine studies adequately described the study population [2, 5-9, 11, 13, 15] . Six studies included samples from non-FNAIT cases [2, 5, [8] [9] [10] 12] and screened eligible patients [2, [5] [6] [7] [8] 12] .
Four studies reported missing data [2, 4, 8, 10] and three studies assessed reproducibility of testing [2, 8, 11] .
The majority of studies defined severe FNAIT as platelets <50 9 10 9 /l. Severe FNAIT was not defined in three studies [10, 12, 15] . The studies differed in three key aspects: (1) the assays used, (2) the time-point at sampling and (3) the populations screened. Ten studies used the MAIPA assay [2, 5, 6, 8-11, 13, 14, 16] . Other methods used were ELISA [7, 12, 16] , the platelet immunofluorescence test (PIFT) [2, 10, 12, 15] the 51 Cr release test [12] and the chemiluminescence assay [8] .
Antibody testing was scheduled across various weeks of gestation. Antibody measurement was conducted once in five studies [8-10, 14, 16] , and more than once in seven studies [2, 5, 7, [11] [12] [13] 15] . The frequency of antibody testing was not reported in one study [6] .
Three studies conducted HPA-1 typing followed by antibody screening and quantitation in unselected pregnancies [2, 5, 7] . Ten studies analyzed samples of known or suspected FNAIT [6, [8] [9] [10] [11] [12] [13] [14] [15] [16] .
The assay and time-point of sampling were taken into consideration when summarizing and discussing the results, that is evaluating studies that used the same laboratory methods, as well as evaluating results from retrospective studies that reported antibody concentrations and fetal or newborn platelet counts at the same timepoint when possible.
Lastly, the results were grouped and described separately, that is prospective screening studies of unselected pregnancies and studies including newly diagnosed FNAIT patients and/or follow-up of women with a history of FNAIT, that is retrospective studies.
Prospective screening studies on unselected pregnancies
Details of the three prospective studies that screened and reported quantitative results from unselected immunized pregnancies (a total of 235/125 000 screened pregnancies) are presented in Table 1 [ 2, 5, 7] . None of these women were treated with intravenous immune globulin (IVIG) during pregnancy. Severely thrombocytopenic neonates (with or without bleeding symptoms) were treated with compatible platelet transfusion immediately after birth.
Antibody level to predict FNAIT: Williamson described that fetal thrombocytopenia (<50 9 10 9 /l) in the third tri- [19] . Hence, all studies (n = 3) reported that the maternal antibody level at delivery correlated with the newborn platelet count when using quantitative MAIPA.
Retrospective studies on suspected FNAIT
The ten studies focusing on suspected patients with FNAIT included a total of 566 women with HPA-1a antibodies [6, [8] [9] [10] [11] [12] [13] [14] [15] [16] . These studies included patients who were treated antenatally either with IVIG (with or without steroids) or with intrauterine platelet transfusions. Eight of the ten studies reported either titration or quantification of HPA-1a antibodies (Table 2 ). In the four studies that reported results obtained from the second trimester, blood samples were collected from the pregnant mother and the fetus at the same time-points; whereas in the five studies that reported results from sampling at birth and/ or the 3rd trimester, samples were only collected simultaneously in three studies [6, [8] [9] [10] [11] [12] [13] 15] .
Antibody level to predict severity of FNAIT
Three studies investigated the HPA-1a antibody level by titration of the samples using either PIFT or ELISA [10, 12, 15] . One of these studies [15] did not examine if there was any correlation between antibody titre and platelet count whilst the two other studies [10, 12] indicated that there was no correlation between the HPA-1a antibody level and neonatal platelet count. Five studies quantified maternal HPA-1a antibodies by quantitative MAIPA [6, 8, 9, 11, 13] . Four of these five studies, which included a total of 313 pregnancies, identified a statistically significant relationship (P-values: 0Á002-0Á046) between HPA-1a antibody level and fetal or neonatal platelet count (<20 9 10 9 /l or <50 9 10 9 /l, see Table 2 ) [6, 9, 11, 13] . From the four studies that reported an association, Sainio did not find a statistically significant correlation in samples taken postnatally in 72 index patients, but identified a statistically significant correlation between maternal HPA-1a antibody level during the second trimester and the corresponding fetal platelet count [11] . In addition, maternal HPA-1a antibody level was significantly higher for those delivering neonates with bleeding symptoms (ICH or mild bleeding symptoms) than in mothers of neonates with FNAIT that there was no evidence of bleeding. Killie reported a significant difference in maternal antibody levels at delivery between cases where neonates were severely thrombocytopenic and neonates with normal platelet count [9] . Bertrand reported that an antibody level of ≥250 AU/ml (corresponding to 31 IU/ml [18]) correlated with severe thrombocytopenia in the fetus before the start of treatment (P = 0Á0021) [6] . At this level, PPV and NPV for a platelet count of 50 9 10 9 /l or less were 94% and 60%, respectively [6] . The same group subsequently reported that in pregnancies treated with IVIG, a mean antibody level throughout pregnancy (area under the curve, AUC) >23 IU/ml correlated with treatment failure (newborn platelet count ≤50 9 10 9 /l) [13]. By using an antibody level of 23 IU/ml as cut-off, the PPV and NPV of therapy failure were 67% and 86%, respectively.
The last of the five studies included 97 newly diagnosed and 36 patients with known FNAIT and did not find any relationship between anti-HPA-1a antibody levels and platelet count in newly diagnosed patients [8] . However, in 22/36 patients who were treated antenatally, maternal HPA-1a antibody levels were reported to correlate with fetal platelet count (after fetal blood sampling [FBS] ). The correlation coefficient was not reported. Overall four of five studies, which used quantitative MAIPA found that the maternal antibody level in second trimester correlated with the fetal platelet count in second trimester (4/5). The last study did not investigate fetal platelet count during second trimester, but reported that maternal antibody level measured at time of delivery correlated with platelet count in the newborn [9] .
It is not known if and how antenatal IVIG treatment potentially affects measurements of anti-HPA-1a antibodies. However, a decrease in HPA-1a antibody concentrations has been observed during pregnancies of IVIGtreated women [6] as well as in untreated women [2] , suggesting that the decrease in antibody level may not be associated with IVIG therapy.
Discussion
Main findings
In this descriptive systematic review, we found that most studies quantifying HPA-1a antibodies by the MAIPA assay reported a correlation between antibody level and severity of FNAIT; whereas studies in which antibody analysis was done by PIFT or ELISA could not document such a relationship, suggesting that these methods may not be as suitable for quantitative analysis. This is supported by the study by Bessos who compared ELISA and MAIPA and found that the severity of FNAIT was significantly associated with the HPA-1a antibody level when using MAIPA, but not when an in-house ELISA was used [19] . Another important finding was that timing of the blood sample for antibody determination from mother and fetus/newborn seems essential since a correlation was only observed in those studies that reported the same time-point for fetal/ newborn platelet count sampling and maternal antibody detection/quantitation.
Results from prospective screening studies using the MAIPA technique [2, 5] (a total of approximately 125 000 pregnancies) showed that among 256 HPA1a-immunized pregnancies, HPA-1a antibody levels in the third trimester or at delivery correlated with the newborn platelet count, suggesting that the maternal HPA-1a antibody level in the third trimester has the potential to be used as a predictive tool and used as guideline for mode of delivery and to have compatible HPA-1bb platelets available in case of bleeding in the neonate.
A significant association (all P < 0Á05) between the fetal platelet count and maternal antibody level quantified by MAIPA could also be demonstrated in pregnancies known to be at risk of FNAIT due to a previous child with FNAIT, when maternal and fetal sampling was performed at the same time during the second trimester [6, 8, 9, 11] . The low PPV and NPV would not allow for the use of maternal antibody level to determine a final diagnosis of severe FNAIT (defined as <20 9 10 9 /l or <50 9 10 9 /l in the studies) or to be used to establish treatment regimens. Bertrand suggests that the maternal antibody level throughout pregnancy (area under the curve, AUC) might be used to follow the effect of IVIG treatment [13] .
Strength and limitations
A strength of this systematic review is that study populations were categorized by FNAIT risk and compared separately; that is results from studies screening unselected pregnancies (prospective studies) and from studies focusing on newly diagnosed FNAIT patients and pregnancies with a known risk of FNAIT (retrospective studies). This has been an important bias in previous study reports. In retrospective studies, cases have been selected who have been diagnosed with FNAIT in the fetus/newborn, and thus, it is not surprising that the majority of these women will have higher antibody levels than women in prospective studies, since the latter studies included all HPA-1a-immunized women irrespective of fetal/neonatal symptoms. It is therefore not surprising there is a better chance of finding an association between antibody levels and fetal/neonatal platelet counts in prospective studies, as compared with retrospective studies, and similarly, it is not surprising that an effort of defining a clinically relevant antibody cut-off level will differ between these two patient populations. In general, measurements reported as fluorescence intensity, optical density, titre or arbitrary units would depend on the in-house assay sensitivity and would not allow for comparison between laboratories. Results could only be compared directly when an international standard was used as a reference, and measurements were reported in IU/ml. As a result, there are two major limitations of the studies included in this review that make it difficult to draw definitive conclusions. Firstly, different methods were used to quantify anti-HPA-1a levels and the number of studies reporting HPA-1a antibody level in IU/ml was small (4/13). Secondly, the time of sampling varied considerably. Samples taken at different time-points cannot be compared directly, primarily because the transfer of maternal IgG across the placenta varies with gestational age. The transfer of normal and pathogenic IgG from the mother to her fetus begins as early as the end of the first trimester and increases as the pregnancy advances [31] . Therefore, the amount of HPA-1a antibodies to which the fetus is exposed, may be related to both maternal antibody concentration and gestational age.
The studies in the current review correlated antibody concentration and platelet count using a low platelet count as a surrogate for bleeding risk. Bleeding is indeed much more common in neonates with very low platelet counts but many fetuses with low platelet counts seem not to bleed. Both a defective haemostatic system as well as endothelial damage are necessary requirements for bleeding to occur. Thus, isolated thrombocytopenia, as such, may not cause harm in the newborn unless the endothelium is damaged. This may explain why some newborns with severe thrombocytopenia do not bleed. Recently, it was demonstrated that HPA-1a antibodies in women who have had a fetus/child with FNAIT-associated ICH bind to aVß3 on endothelial cells, and that these antibodies in vitro can induce endothelial apoptosis. These antibodies were not present in HPA-1a-immunized women whose fetus/child had FNAIT but no ICH [32] . Unfortunately, the current MAIPA assays do not distinguish between these different specificities of the HPA-1a antibodies. Moreover, the reactivity of antibodies measured by MAIPA or similar techniques is always a composite of antibody amount, specificity and avidity. Moreover, the exact binding sites (epitopes) for the HPA-1a antibodies would be important, since binding sites might alter binding to and/or signalling through the fibrinogen receptor, and thus may have influence on FNAIT severity and bleeding tendency [33] . Further, low-avidity antibodies can have biological effects as they are not washed away in vivo as opposed to in vitro, and such antibodies may account for those few cases where a fetus/child bleeds despite the MAIPA assay only detected low levels of anti-HPA-1a.
Implications
Fetal/neonatal alloimmune thrombocytopenia has been regarded as the platelet counterpart of haemolytic disease of the fetus and newborn (HDFN). For decades, measurement of the maternal anti-D level, either as titre or as IU/ ml, has been used in Europe and North America to determine when an RhD-immunized woman is referred to a fetal medicine unit for monitoring and eventual treatment. An RhD-alloimmunized pregnant woman is referred to a fetal medicine unit for monitoring the middle cerebral artery peak systolic velocity (MCA PSV) when the antibody level exceeds 4 IU/ml. Invasive investigation or treatment may be required when the anti-D level exceeds 15 IU/ml, but this is ultimately determined by the MCA PSV levels [34] [35] [36] . Results from the prospective studies suggest that HPA-1a antibody levels might have a comparable future role as predictor for fetuses with increased risk for FNAIT. As there remains interlaboratory variation in the measurement of the anti-D titre [37] , some of the inconsistencies in anti-HPA-1a antibody titre we found in some of reports may represent a similar occurrence. Although a gold standard imaging modality is not yet available, and there is a lack of consensus on how to treat risk pregnancies that are identified by screening, anti-HPA-1a levels may identify pregnancies to be referred to specialists in fetal-maternal medicine. Hence, if screening for FNAIT is implemented, measurements of HPA-1a antibody levels could potentially be used for risk stratification of pregnancies and could guide the clinicians in order to avoid invasive procedures in pregnancies with low risk, and for planning the route of delivery and treatment of high-risk pregnancies. Preliminary data suggest [36, 37] an antibody cut-off of 3 IU/ml may potentially be used for risk assessment.
Studies have shown that by standardizing quantitative MAIPA and by expressing anti-HPA-1a levels in IU/ml, it is possible to obtain comparable results across laboratories [38, 39] , and therefore, the differences in HPA-1a antibody cut-off level (3 IU/ml at delivery vs 30 IU/ml in the second trimester [6, 8] ) between prospective and retrospective studies may not necessarily be due to interlaboratory variability. Instead, the difference between the identified antibody threshold may be due to variable trans-placental transportation of IgG during pregnancy. In the second trimester, the fetal IgG level is only 5-10% of the maternal IgG concentration; whereas, later in the third trimester, IgG concentration is almost identical in the mother and fetus [40] . It is also important to be aware that maternal antibody levels increase shortly after delivery and post-partum sampling cannot be used to study the correlation between maternal antibody levels and newborn platelet count.
Although the HPA-1a antibody concentration, as measured by the MAIPA assay, appears to be associated with the degree of thrombocytopenia in FNAIT, there are shortcomings which make it difficult to predict individual risk of bleeding. Thus, more studies are needed to define antibody characteristics that give higher PPV or NPV for bleeding risk; preferentially predictive values in the same range as MCA PSV for the prediction of anaemia in women who are RhD-immunized. Future studies should be prospective, should report the exact time-point of sampling (which ideally would also be standardized), should perform quantitative HPA-1a analysis by the MAIPA assay, should report HPA-1a antibody levels in IU/mL using WHO HPA-1a international standards [41] , and should measure the antibody concentration prior to antenatal treatment as well as during antenatal treatment.
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